Program
Olanzapine
Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.
Drug pageOlanzapine: every studyMany companies study it; this page follows only the 54 they lead. All 266 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 360 open or running | phase 4since Apr 30, 2002 | Apr 30, 2002 | none ahead |
| Viatrisits history only | 50 open or running | phase 4since Oct 12, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 2, 2012 | Jan 2, 2012 | none ahead |
| Abbottits history only | 20 open or running | phase 4since Oct 16, 2003 | Oct 16, 2003 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 3since May 2, 2002 | May 2, 2002 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since May 11, 2014 | May 11, 2014 | none ahead |
| Joint Stock Company "Farmak"its history only | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Neurelisits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
| Orexigen Therapeuticsits history only | 10 open or running | phase 2since Aug 12, 2008 | Aug 12, 2008 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 1since Mar 13, 2024 | Mar 13, 2024 | none ahead |
Also a collaborator on its studies: Pfizer and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Apr 30, 2002.
- Feb 8, 2008Phase 3 study in Bipolar I DisorderEli Lilly · NCT00618748 · 101 enrolled · Japan
- Mar 18, 2008Phase 3 study in SchizophreniaEli Lilly · NCT00640510 · 34 enrolled · Japan
- Mar 30, 20083 phase 1 studies in HealthyViatris · NCT00648921, NCT00647972, NCT00647777
- Aug 12, 2008Orexigen Therapeutics’ first study: phase 2 study in SchizophreniaNew to Orexigen TherapeuticsOrexigen Therapeutics · NCT00734435 · 26 enrolled · United States
- Oct 3, 2008Phase 4 study in Bipolar DisorderEli Lilly · NCT00767715 · 11 enrolled · Sweden
- Aug 12, 2009Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT00958568 · 892 enrolled · United States, Argentina, India and more
- Sep 1, 2009Phase 3 study in SchizophreniaEli Lilly · NCT00970281 · 91 enrolled · Japan
- Jan 2, 2012Dr. Reddy's Laboratories’ first studies: 4 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01503450, NCT01503437, NCT01503424 and 1 more
- Sep 7, 2012Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT01687478 · 176 enrolled · China
- May 11, 2014HK inno.N’s first study: phase 4 study in SchizophreniaNew to HK inno.NHK inno.N · NCT02137993 · 64 enrolled
- Nov 15, 2021Joint Stock Company "Farmak"’s first study: phase 1 study in PharmacokineticsNew to Joint Stock Company "Farmak"Joint Stock Company "Farmak" · NCT05123976 · 32 enrolled · Czechia
- Mar 27, 2023Qilu Pharmaceutical’s first study: phase 3 study in Acute AgitationNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT05803642 · 318 enrolled
- Mar 13, 2024Teva Pharmaceutical Industries’ first study: phase 1 study in SchizophreniaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06319170 · 106 enrolled · United States
- Sep 6, 2024Neurelis’s first study: phase 1 study in HealthyNew to NeurelisNeurelis · NCT06600477 · 24 enrolled · Jordan
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06600477Healthy · Jordan | 1 | Completed | Neurelis | Nov 1, 2023 | 24 |
| NCT06319170Schizophrenia · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 15, 2025 | 106 |
| NCT05803642Acute Agitation | 3 | UNKNOWN | Qilu Pharmaceutical | May 7, 2024 | 318 |
| NCT05123976Pharmacokinetics · Czechia | 1 | Completed | Joint Stock Company "Farmak" | Nov 30, 2020 | 32 |
| NCT02137993Schizophrenia | 4 | Completed | HK inno.N | May 2013 | 64 |
| NCT01687478Depressive Disorder, Treatment-Resistant · China | 3 | Terminated | Eli Lilly | Nov 2015 | 176 |
| NCT01503450Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | Dec 2006 | 26 |
| NCT01503437Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2006 | 22 |
| NCT01503424Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 48 |
| NCT01503398Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 48 |
| NCT00970281Schizophrenia · Japan | 3 | Completed | Eli Lilly | Apr 2011 | 91 |
| NCT00958568Depressive Disorder, Treatment-Resistant · United States, Argentina, India and more | 3 | Completed | Eli Lilly | Mar 2012 | 892 |
| NCT00767715Bipolar Disorder · Sweden | 4 | Terminated | Eli Lilly | Apr 2005 | 11 |
| NCT00734435Schizophrenia · United States | 2 | Terminated | Orexigen Therapeutics | Dec 2008 | 26 |
| NCT00648921Healthy · United States | 1 | Completed | Viatris | Jul 2003 | 30 |
| NCT00647972Healthy · United States | 1 | Terminated | Viatris | May 2003 | 32 |
| NCT00647777Healthy · United States | 1 | Completed | Viatris | Jul 2003 | 32 |
| NCT00640510Schizophrenia · Japan | 3 | Completed | Eli Lilly | Jul 2008 | 34 |
| NCT00618748Bipolar I Disorder · Japan | 3 | Completed | Eli Lilly | Sep 2010 | 101 |
| NCT00510146Bipolar Disorder · China, Japan, Korea, Republic of | 3 | Completed | Eli Lilly | Mar 2010 | 514 |
| NCT00485771Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 403 | |
| NCT00402324Bipolar I Disorder · United States | 4 | Completed | Eli Lilly | Feb 2008 | 202 |
| NCT00401973Schizophrenia · United States, Brazil, Israel and more | 3 | Completed | Eli Lilly | Sep 2008 | 199 |
| NCT00347425Schizophrenia · United States, Argentina, Canada and more | 3 | Completed | Abbott | Feb 2008 | 286 |
| NCT00337662Schizophrenia · United States, Argentina, Russian Federation | 4 | Completed | Eli Lilly | Dec 2007 | 628 |
| NCT00303602Schizophrenia · United States, Canada, Mexico and more | 4 | Completed | Eli Lilly | Dec 2007 | 149 |
| NCT00266630Mania · Japan | 3 | Completed | Eli Lilly | May 2009 | 139 |
| NCT00259272Bipolar Disorder I or II · France | 3 | Completed | Eli Lilly | May 2008 | 141 |
| NCT00239109Schizophrenia · Spain | 4 | Completed | Viatris | 112 | |
| NCT00191997Bipolar Disorder · Spain | 4 | Completed | Eli Lilly | 180 | |
| NCT00191828Weight Gain · Italy | 4 | Completed | Eli Lilly | 60 | |
| NCT00191555Schizophrenia · France | 4 | Completed | Eli Lilly | 360 | |
| NCT00190892Bipolar Disorder · Australia, Greece, Hungary and more | 4 | Completed | Eli Lilly | 120 | |
| NCT00190749Schizophrenia · United States | 4 | Completed | Eli Lilly | Jun 2008 | 130 |
| NCT00145444Schizophrenia · Belgium, Netherlands | 3 | Completed | Viatris | 100 | |
| NCT00129220Bipolar Disorder · Japan | 3 | Completed | Eli Lilly | Jan 2009 | 224 |
| NCT00113594Schizophrenia · United States, Puerto Rico, Russian Federation | 3 | Completed | Eli Lilly | 100 | |
| NCT00103571Schizophrenia · United States, Puerto Rico | 4 | Completed | Eli Lilly | 600 | |
| NCT00100776Schizophrenia · United States | 4 | Completed | Eli Lilly | 600 | |
| NCT00094549Bipolar Disorder · United States, Lithuania, Puerto Rico and more | 4 | Completed | Eli Lilly | 500 | |
| NCT00091650Borderline Personality Disorder · United States, Belgium, France and more | 3 | Completed | Eli Lilly | 300 | |
| NCT00090012Schizophrenia · United States | 4 | Completed | Eli Lilly | 340 | |
| NCT00088491Schizophrenia · Finland, Turkey | 3 | Completed | Eli Lilly | 1,205 | |
| NCT00088465Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Dec 2010 | 931 |
| NCT00088049Schizophrenia · United States | 4 | Completed | Eli Lilly | 560 | |
| NCT00088036Borderline Personality Disorder · United States, Argentina, Poland and more | 3 | Completed | Eli Lilly | 450 | |
| NCT00071253Bipolar Disorder · United States | 4 | Terminated | Abbott | 180 | |
| NCT00051298Schizophrenia · United States, Russian Federation | 3 | Completed | Eli Lilly | 107 | |
| NCT00050206Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 130 | |
| NCT00036088Schizophrenia · United States, Argentina, Austria and more | 4 | Completed | Eli Lilly | 530 | |
| NCT00035321Depressive Disorder, Major · United States, Canada | 3 | Completed | Eli Lilly | 600 | |
| NCT00034892Schizophrenia · United States, Canada | 3 | Completed | AstraZeneca | Mar 2005 | |
| NCT00034801Depression · United States | 4 | Completed | Eli Lilly | 378 | |
| NCT00034580Bipolar Disorder · United States | 4 | Completed | Eli Lilly | 326 |
How it is read
Names in the registry
- “Olanzapine”, 33 entries
- “olanzapine”, 17 entries
- “ALKS 3831”, 7 entries
- “Olanzapine Tablets 5 mg”, 2 entries
- “Olanzapine OD Tablets 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 41 studies
- Bipolar Disorder, 12 studies
- Depressive Disorder, Treatment-Resistant, 2 studies
- Fasting, 2 studies
- Borderline Personality Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.